However, unresolved conflicts in 2012 concerning prostate-specific antigen (PSA) screening recommendations could explain the disproportionately higher occurrence of negative prostate cancer outcomes due to increases in regional‐stage and distant‐stage diagnoses. This evidence concerns the gene KLK3 and prostate carcinoma.